A Phase II Study of Poziotinib in EGFR Exon 20 Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)

Trial Profile

A Phase II Study of Poziotinib in EGFR Exon 20 Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs Poziotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Nov 2017 Planned number of patients changed from 60 to 80.
    • 18 Oct 2017 Results (n=8) presented at the 18th World Conference on Lung Cancer.
    • 17 Oct 2017 According to a Spectrum Pharmaceuticals media release, interim results were presented at 18th IASLC World Conference on Lung Cancer in Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top